CD4 and melanoma: Interestingly, targeting LDH‐A in SkMel28 male melanoma cells by silencing or by administration of the selective inhibitor FX‐11 resulted in a significant reduction in the migration of CD4+ cells towards SkMel28 male melanoma cells (Fig. 2D–F), as a result of a decreased tumoural lactate release (Fig. 2G,H), without a toxic effect induced by FX‐11 treatment on CD4+ T cells (Fig. 2I).